AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright

Stock News

Sep 01

H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a "Buy" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.

Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1183251394"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183251394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183251394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183251394","market":"sg","top_or_hot":-1,"title":"AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright","media":"Stock News","content":"<p>H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.</p>\n<p>Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-01 14:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.</p>\n<p>Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720050803.USD","symbol_name":"安联全方位中国股票基金","start_time":0,"source_url":"","article_id":"1183251394","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183251394","pubTimestamp":1756707626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","LU1720050803.USD":"安联全方位中国股票基金","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","BK1574":"生物医药B类股","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK4139":"生物科技","SMMT":"Summit Therapeutics PLC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","06978":"永泰生物-B","09926":"康方生物"},"translate_title":"康方生物的创新药物优势促使合作伙伴Summit Therapeutics(SMMT.US)H.C.将目标价上调至50美元。温赖特","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"09926":1,"SMMT":1},"content_text":"H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.\nSummit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}